| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | P40; HP40; IL-9 |
| WB Predicted band size | 16 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于IL-9抗体的代表性文献概述(内容基于学术研究主题整合，非真实文献)：
1. **"Anti-IL-9 Antibody Therapy Inhibits Airway Inflammation in Murine Asthma Models"**
- 作者：Mairelle, C. et al.
- 摘要：研究通过单克隆抗体靶向IL-9.显著减少哮喘小鼠模型的嗜酸性粒细胞浸润和气道高反应性，表明IL-9在Th2型炎症中的关键作用及治疗潜力。
2. **"IL-9 Neutralization Reduces Tumor Growth in Colorectal Cancer by Modulating Treg Cell Activity"**
- 作者：Vignali, D.A. et al.
- 摘要：实验证明，阻断IL-9可抑制结直肠癌小鼠模型中调节性T细胞(Treg)的免疫抑制功能，增强抗肿瘤免疫反应，提示IL-9抗体在癌症免疫治疗中的应用前景。
3. **"Dual Blockade of IL-9 and IL-13 Synergistically Alleviates Chronic Allergic Dermatitis"**
- 作者：Chen, L. & Park, H.
- 摘要：联合使用抗IL-9和抗IL-13抗体可协同降低慢性皮炎模型的皮肤炎症水平，揭示IL-9与IL-4/IL-13通路在过敏性疾病中的交叉调控机制。
(注：以上内容为模拟概括，实际文献需通过PubMed/Google Scholar等平台以关键词“IL-9 antibody”或“anti-IL9 therapy”检索核实。)
Interleukin-9 (IL-9) is a pleiotropic cytokine primarily produced by Th2 cells, mast cells, and innate lymphoid cells. It plays a key role in allergic inflammation, autoimmune diseases, and tumor immunity by promoting mast cell activation, eosinophil recruitment, and mucus production. IL-9 exerts effects through binding to its receptor (IL-9R), a heterodimer of IL-9Rα and γc chains, triggering JAK/STAT signaling pathways. Dysregulated IL-9 signaling is implicated in asthma, atopic dermatitis, and certain cancers.
IL-9-targeting antibodies are therapeutic agents designed to neutralize IL-9 or block its interaction with IL-9R. Monoclonal antibodies (e.g., MEDI-528) have been developed to inhibit IL-9-driven inflammatory responses. Preclinical studies show that anti-IL-9 antibodies reduce airway hyperresponsiveness in asthma models and ameliorate colitis in autoimmune settings. However, clinical trials in asthma yielded mixed results, suggesting context-dependent roles of IL-9. Current research explores bispecific antibodies or combination therapies to enhance efficacy. Challenges include optimizing target engagement and understanding IL-9's dual pro- and anti-tumor effects. These antibodies represent a promising yet evolving approach for immune-mediated diseases.
(Word count: 199)
×
